- Senior Investigator, Clinical Genetics Branch
Dr. Wentzensen received an M.D. from the University of Heidelberg in 2000. He trained in general surgery and conducted research in surgical oncology in the Department of Surgery, University of Heidelberg from 2000-2002. From 2002-2007, Dr. Wentzensen earned his Ph.D. (Habilitation) in Applied Tumor Biology at the Institute of Pathology, University of Heidelberg. During this time, he conducted research in molecular biology, molecular pathology, and molecular epidemiology of cervical cancer. He built a research group focusing on cervical cancer biomarker discovery and validation and established a diagnostic laboratory for cervical cancer screening. From 2005-2007, he earned a Master of Epidemiology at the University of Mainz. Dr. Wentzensen joined DCEG as a visiting fellow in 2007, became a tenure-track investigator in 2009, and was awarded scientific tenure by the NIH and appointed senior investigator in 2013.
Articles2
- (2020). The D2 and D3 Sublineages of Human Papilloma Virus 16-Positive Cervical Cancer in Guatemala Differ in Integration Rate and Age of Diagnosis. CANCER RESEARCH. 80(18), 3803-3809.
- (2020). Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications. 11(1),
Academic Articles408
- (2020). Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infectious Agents and Cancer. 15(1),
- (2020). Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 29(10), 2010-2018.
- (2020). Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 24(4), 426-426.
- (2020). Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. STATISTICS IN MEDICINE.
- (2020). The D2 and D3 Sublineages of Human Papilloma Virus 16-Positive Cervical Cancer in Guatemala Differ in Integration Rate and Age of Diagnosis. CANCER RESEARCH. 80(18), 3803-3809.